Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers. The Company’s most advanced drug candidate, CUDC-907, is currently being investigated in a Phase 2 clinical trial in patients with MYC altered diffuse large B-cell lymphomas and in a Phase 1 trial in patients with solid tumors.
Curis is engaged in a broad collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology. As part of this collaboration, Curis has the exclusive license to orally-available small molecule antagonists of the PD-1 and VISTA pathways, including the IND-stage molecule CA-170, a PD-L1/VISTA antagonist. The Company has also selected a second program that focuses on small molecule antagonists of PD-1 and TIM3 pathways including compounds that target PD-L1/TIM3 immune checkpoints as part of the collaboration with Aurigene. Curis has also licensed the exclusive rights to orally-available small molecule inhibitors of the IRAK4 kinase including the development candidate CA-4948 from Aurigene.
The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge® (vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Roche and Genentech are continuing Erivedge®’s clinical development in less severe forms of BCC as well as in other diseases including idiopathic pulmonary fibrosis, or IPF, and myelofibrosis.